Valuation: Moderna, Inc.

Market Cap 22.62B 19.87B 18.48B 16.96B 31.86B 2,179B 32.35B 219B 85.73B 1,071B 84.93B 83.1B 3,704B P/E 2026 *
-6.59x
P/E 2027 * -12x
Enterprise Value 19.22B 16.88B 15.7B 14.4B 27.07B 1,851B 27.48B 186B 72.83B 910B 72.15B 70.59B 3,146B EV / Sales 2026 *
9.17x
EV / Sales 2027 * 8.06x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-4.96%
1 week-12.10%
Current month-22.40%
1 month-10.06%
3 months+7.12%
6 months+13.23%
Current year+84.27%
1 week 53.85
Extreme 53.85
62.43
1 month 53.85
Extreme 53.85
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
Change 5-day change 1-year change 3-year change Capi.($)
-4.92%-12.10%+59.78%-55.82% 22.62B
+1.19%-2.62%+16.70%-9.38% 66.32B
+1.23%+2.80%+37.51%+202.14% 52.6B
+10.08%+51.80%+51.80%+51.80% 43.27B
-1.32%-6.34%-56.98%-57.24% 38.64B
+1.06%-1.72%+52.69%-26.91% 29.62B
+1.02%+0.47%+67.12%+85.63% 23.31B
-1.21%-4.51%+2.22%+174.24% 20.22B
-0.22%-0.95%+61.97%+123.78% 16.29B
+1.24%+3.08%+83.73%+152.38% 16.26B
Average +0.80%-0.87%+37.65%+64.06% 32.92B
Weighted average by Cap. +1.39%-0.45%+30.42%+54.66%

Financials

2026 *2027 *
Net sales 2.1B 1.84B 1.71B 1.57B 2.95B 202B 3B 20.32B 7.94B 99.19B 7.86B 7.7B 343B 2.55B 2.24B 2.08B 1.91B 3.59B 246B 3.65B 24.75B 9.67B 121B 9.58B 9.37B 418B
Net income -3.41B -2.99B -2.78B -2.56B -4.8B -328B -4.88B -33.07B -12.92B -161B -12.8B -12.52B -558B -1.85B -1.62B -1.51B -1.39B -2.6B -178B -2.64B -17.94B -7.01B -87.55B -6.94B -6.79B -303B
Net Debt -3.41B -2.99B -2.78B -2.55B -4.8B -328B -4.87B -33.04B -12.91B -161B -12.79B -12.51B -558B -2.05B -1.8B -1.68B -1.54B -2.89B -198B -2.94B -19.91B -7.78B -97.2B -7.71B -7.54B -336B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
24/07/26 US$54.25 -4.86% 2,858,772
23/07/26 US$57.02 -1.81% 4,695,588
22/07/26 US$58.07 -2.67% 3,780,416
21/07/26 US$59.66 +0.29% 4,357,386
20/07/26 US$59.49 -3.77% 4,967,920
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
57.02USD
Average target price
49.37USD
Spread / Average Target
-13.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock